Welcome to our dedicated page for Viracta Therapeutics news (Ticker: VIRX), a resource for investors and traders seeking the latest updates and insights on Viracta Therapeutics stock.
Viracta Therapeutics reports company developments tied to its former clinical-stage precision oncology programs and its wind-down process. The company focused on virus-associated cancers, with Nana-val, an all-oral combination of nanatinostat and valganciclovir, developed for EBV-positive lymphomas and other EBV-positive cancers through studies including NAVAL-1.
Recent news centers on the closure of the NAVAL-1 trial, resource reprioritization, workforce and board changes, quarterly business updates, employment inducement grants, strategic-alternative reviews for development programs, and the announced wind down of operations.
Viracta Therapeutics, a clinical-stage precision oncology company, is set to present at the RBC Capital Markets Global Healthcare Conference. The event will feature the President and CEO, Mark Rothera, and the Chief Medical Officer, Dr. Darrel P. Cohen. The presentation is scheduled for May 14, 2024, at 11:00 a.m. EDT and will be available for live webcast and archived on the Viracta website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.